Scientists Uncover a 45-Gene Signature That Predicts Prostate Cancer Spread

One of the most frustrating uncertainties in prostate cancer care may finally be losing some of its grip. Most men diagnosed with seemingly localized disease do well after surgery or radiation, but a stubborn minority harbor tumors that quietly acquire the ability to seed distant organs, often years later. Clinicians have long lacked a reliable way to tell these two groups apart at the time of diagnosis. Now, a team led by researchers at Cedars-Sinai Medical Center, working with collaborators at Weill Cornell Medicine, Duke-affiliated cohorts, and institutions in Italy, reports the development and validation of a gene-expression signature called Met-Score that quantifies what they term metastatic competence directly from primary tumor tissue. The study, published in the Journal of Translational Medicine, suggests that the biological potential to metastasize is written into the transcriptome of the original tumor long before any secondary lesion appears.

The scientific premise behind the work is deceptively simple. If some primary tumors are intrinsically competent to spread, then the cells within those tumors should express a recurring set of genes that distinguishes them from tumors that remain indolent. To find that set, the researchers aggregated gene-expression data from six independent cohorts of primary prostate tumors, encompassing 1,000 patients and 306 documented metastatic events. Rather than pooling raw data, they applied a random-effects meta-analysis, a statistical framework that estimates a pooled effect size for each gene while explicitly accounting for between-study heterogeneity. For every gene, they computed Hedges’ g, a standardized measure of effect magnitude, along with Cochran’s Q and the I-squared statistic to quantify how consistently the effect held across studies. Genes were retained only if their direction of change was reproducible, yielding a 45-gene metastatic progression program: 27 genes up-regulated and 18 down-regulated in tumors that ultimately metastasized.

With the signature defined, the team converted it into a clinically deployable instrument. They trained an L2-regularized logistic regression model, a form of ridge regression that penalizes large coefficients to prevent overfitting, using the 45 genes as predictors and metastatic progression as the outcome. Crucially, the model coefficients were locked once trained and then applied unchanged to completely independent validation cohorts, with no per-cohort refitting. This frozen-deployment design is a rigorous test of generalizability, because many biomarker studies quietly recalibrate their models to each new dataset, inflating apparent performance. In the Johns Hopkins Natural History cohort of 239 patients with 93 metastatic events, the locked Met-Score achieved competing-risk time-dependent AUCs of 0.75 at five years and 0.71 at ten years. In the Durham Veterans Affairs cohort of 555 patients with 40 events, the corresponding AUC was 0.79 at both time horizons. A pooled meta-analytic AUC across the development cohorts reached 0.81.

Discrimination alone is not enough; a biomarker must add information beyond what clinicians already measure. The investigators therefore tested whether Met-Score remained associated with metastasis-free survival after adjustment for pathological Gleason grade, the standard histologic measure of tumor aggressiveness. It did, in both validation cohorts. Even more intriguing were exploratory analyses confined to Gleason 7 disease, the large and clinically ambiguous middle category where treatment decisions are most contested. Within this group, Met-Score appeared to resolve additional risk beyond Grade Group alone, suggesting that two men with histologically identical tumors could carry very different metastatic potentials. The authors are careful to note that this finding requires prospective confirmation, but it points toward a future in which transcriptomic profiling could spare low-risk patients aggressive therapy while intensifying surveillance for those whose tumors carry a hidden program of spread.

The signature also proved its worth on diagnostic biopsy material, which is what clinicians actually have in hand at diagnosis. In cross-sectional RNA-sequencing cohorts of diagnostic biopsies, Met-Score separated de novo metastatic, hormone-naïve disease from localized disease with striking accuracy, achieving AUCs between 0.93 and 0.98. This is a critical technical point: a biomarker that only works on surgically resected prostatectomy specimens is of limited use for risk stratification at the moment of decision-making. The biopsy results indicate that the metastatic competence program is detectable in the small amount of tissue obtained through a needle, supporting the idea that the biology of spread is present from the outset rather than acquired only late in the disease course.

To understand where in the tumor ecosystem the signature resides, the researchers turned to single-cell RNA sequencing of tumor biopsies spanning localized disease, metastatic hormone-sensitive disease, and metastatic castration-resistant disease. The analysis revealed that tumor cells in metastatic disease carried significantly higher Met-Score activity than tumor cells in localized tumors, with the signal concentrated in proliferative transcriptional programs. Equally notable was the cell-type-restricted expression pattern of the component genes: individual genes within the signature were expressed in markedly different cellular compartments, meaning the composite score integrates both malignant-cell-intrinsic programs and features of the surrounding microenvironment. This decomposition matters because it reframes metastatic competence not as a property of tumor cells alone but as a coordinated transcriptional state spanning multiple cell populations.

The bone metastatic niche provided a second vantage point. In a dataset examining bone marrow and bone metastasis samples, Met-Score showed cell-type-specific enrichment in tumor tissue relative to distal marrow, with particularly strong signal among lymphoid populations. This observation hints that the immune and stromal composition of the metastatic niche may echo, or even support, the transcriptional program measured in the primary tumor. Whether the signature reflects a pre-adaptation of the tumor, a permissive niche, or both remains an open question, but the concordance across anatomical sites strengthens the case that Met-Score captures a conserved biological program rather than a cohort-specific artifact.

Perhaps the most forward-looking result concerns therapeutic responsiveness. In a patient-derived xenograft model of metastatic bone disease, Met-Score declined after treatment with batiraxcept, an agent targeting the AXL-ALK and related signaling axis, and the score shifted concordantly across independent genetic and pharmacologic perturbation datasets. In practical terms, this means the transcriptional program is not a fixed, inert label; it moves when the underlying biology is pushed. A biomarker that responds to perturbation can in principle serve as a pharmacodynamic readout, allowing researchers to test whether candidate therapies actually dismantle the metastatic competence state in early-phase trials, long before survival endpoints mature.

The study also subjected its own construction to unusually thorough robustness testing. A leave-one-cohort-out sensitivity analysis recomputed per-gene statistics after iteratively excluding each discovery cohort, confirming that effect directions and significance were stable. Nested internal-external cross-validation compared the full 45-gene ridge model against trimmed top-10 and top-20 variants, LASSO, and elastic net alternatives, and the frozen signature held its performance against models retrained from scratch. Secondary endpoints in the Durham VA cohort, including prostate cancer-specific mortality, overall survival, and biochemical recurrence, were analyzed with competing-risk methods, and decision-curve analyses evaluated the clinical net benefit of adding Met-Score to a baseline model of Grade Group, PSA, and pathological T stage. Sensitivity analyses addressed tumor purity, race-specific effects, landmark times, and adjustment for a cell-cycle progression gene score, all of which the association between Met-Score and metastasis survived.

Caveats remain, and the authors state them plainly. The Gleason 7 findings are exploratory; the validation cohorts, while independent, are retrospective; and the model was trained on bulk expression data whose biological interpretation depends on the single-cell and perturbation analyses that support it. Prospective evaluation will be required before Met-Score can inform treatment decisions. Even so, the convergence of evidence is compelling: a reproducible, biologically interpretable, 45-gene program detectable in primary tumors and diagnostic biopsies, enriched in proliferative tumor cells, reflected in the metastatic niche, and responsive to therapeutic perturbation. If prospective trials confirm its value, Met-Score could shift prostate cancer risk stratification from a discipline of looking backward at histology toward one of reading forward from the tumor’s own transcriptional blueprint, identifying at diagnosis which cancers carry the seeds of metastasis and which do not.

Subject of Research: A transcriptomic biomarker for predicting metastatic progression in primary prostate cancer

Article Title: A conserved metastatic competence signature from primary prostate tumors

Article References: Valencia, I., Vasanthakumari, P., Aghmiouni, M. R., Magana, B., Nuzzo, P. V., Kim, M., Francini, E., Ravera, F., Fanelli, G. N., Bleve, S., Scatena, C., Marchionni, L., Freedland, S. J., You, S., & Omar, M. (2026). A conserved metastatic competence signature from primary prostate tumors. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09046-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09046-5

Keywords: prostate cancer, metastasis, Met-Score, gene expression signature, biomarker, risk stratification, transcriptomics, single-cell RNA sequencing, tumor microenvironment, Gleason grade, diagnostic biopsy, prognostic marker